PDF
Easy Read
Abridged PDF
Respond to this article- Versions
- bmj.39345.405243.BEv1
- 335/7627/982 most recent
- I Petersen, statistician1,
- A M Johnson, head of department1,
- A Islam, database manager1,
- G Duckworth, consultant epidemiologist2,
- D M Livermore, microbiologist2,
- A C Hayward, senior lecturer infectious disease epidemiology1
- 1UCL Centre for Infectious Disease Epidemiology, Department of Primary Care and Population Sciences, University College London, London NW3 2PQ
- 2Health Protection Agency, Centre for Infections, London NW9 5EQ
- Correspondence to: A Hayward a.hayward{at}pcps.ucl.ac.uk
- Accepted 13 August 2007
Abstract
Objective To determine the extent to which antibiotics reduce the risk of serious complications after common respiratory tract infections.
Design Retrospective cohort study.
Setting UK primary care practices contributing to the general practice research database.
Data source 3.36 million episodes of respiratory tract infection.
Main outcome measures Risk of serious complications in treated and untreated patients in the month after diagnosis: mastoiditis after otitis media, quinsy after sore throat, and pneumonia after upper respiratory tract infection and chest infection. Number of patients needed to treat to prevent one complication.
Results Serious complications were rare after upper respiratory tract infections, sore throat, and otitis media, and the number needed to treat was over 4000. The risk of pneumonia after chest infection was high, particularly in elderly people, and was substantially reduced by antibiotic use, with a number needed to treat of 39 for those aged ≥65 and 96-119 in younger age groups.
Conclusion Antibiotics are not justified to reduce the risk of serious complications for upper respiratory tract infection, sore throat, or otitis media. Antibiotics substantially reduce the risk of pneumonia after chest infection, particularly in elderly people in whom the risk is highest.
Footnotes
Contributors: ACH was chief investigator, had the original idea for the study, and developed the analytical strategy with IP. The study plan was refined with input from all authors. IP analysed the data. AI extracted the relevant data from the database. IP and ACH drafted the paper, incorporating comments from the other authors. ACH is guarantor.
Funding: Department of Health.
Competing interests: DML has various shareholdings and grants from pharmaceutical companies. AMJ has undertaken brief consultancy for GlaxoSmithKline in HPV epidemiology.
Ethical approval: GPRD scientific and ethical advisory committee.
Provenance and peer review: Not commissioned; externally peer reviewed.
- Accepted 13 August 2007
CiteULike
Connotea
Del.icio.us
Digg
Facebook
Mendeley
Reddit
Technorati
Twitter
Stumbleupon
Rapid responses
Latest Responses
Re: Cholinesterase inhibitors and memantine for symptomatic treatment of dementia
Published 27 May 2012
Re: Time to end the distinction between mental and neurological illnesses
Published 27 May 2012
Re: Influenza vaccination in healthcare professionals
Published 27 May 2012
Greek doctors are required to deliver care all week at no cost!
Published 27 May 2012
Re: What is recall bias?
Published 27 May 2012
Most responses
Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10 (12 responses)
Published 10 May 2012 - 23:32
The psychiatric oligarchs who medicalise normality (9 responses)
Published 2 May 2012
Are doctors justified in taking industrial action in defence of their pensions? No (8 responses)
Published 8 May 2012 - 12:21
Are doctors justified in taking industrial action in defence of their pensions? Yes (8 responses)
Published 8 May 2012 - 12:21
The hardest thing: admitting error (7 responses)
Published 2 May 2012 - 12:27